JP2024525612A5 - - Google Patents
Info
- Publication number
- JP2024525612A5 JP2024525612A5 JP2024500480A JP2024500480A JP2024525612A5 JP 2024525612 A5 JP2024525612 A5 JP 2024525612A5 JP 2024500480 A JP2024500480 A JP 2024500480A JP 2024500480 A JP2024500480 A JP 2024500480A JP 2024525612 A5 JP2024525612 A5 JP 2024525612A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- oligonucleotide
- optionally
- complex according
- complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163220030P | 2021-07-09 | 2021-07-09 | |
| US63/220,030 | 2021-07-09 | ||
| PCT/US2022/073534 WO2023283619A2 (en) | 2021-07-09 | 2022-07-08 | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024525612A JP2024525612A (ja) | 2024-07-12 |
| JP2024525612A5 true JP2024525612A5 (enExample) | 2025-07-17 |
Family
ID=84802094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024500480A Pending JP2024525612A (ja) | 2021-07-09 | 2022-07-08 | 筋標的化複合体およびジストロフィノパチーを処置するためのその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240382609A1 (enExample) |
| EP (1) | EP4367142A4 (enExample) |
| JP (1) | JP2024525612A (enExample) |
| KR (1) | KR20240032946A (enExample) |
| CN (1) | CN118401553A (enExample) |
| CA (1) | CA3226300A1 (enExample) |
| IL (1) | IL309911A (enExample) |
| WO (1) | WO2023283619A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3108282A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| SG11202100928QA (en) | 2018-08-02 | 2021-02-25 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| JP2024525608A (ja) | 2021-07-09 | 2024-07-12 | ダイン セラピューティクス，インコーポレーテッド | ジストロフィン異常症を処置するための筋標的化複合体および製剤 |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| IL316143A (en) | 2022-04-15 | 2024-12-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy |
| AU2024299328A1 (en) | 2023-07-21 | 2026-01-22 | Marrow Therapeutics, Inc. | Hematopoietic cell targeting conjugates and related methods |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2639852T3 (es) * | 2007-10-26 | 2017-10-30 | Academisch Ziekenhuis Leiden | Medios y métodos para contrarrestar los trastornos musculares |
| CA3108282A1 (en) * | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| IL312067B2 (en) * | 2018-12-21 | 2025-08-01 | Avidity Biosciences Inc | Anti-transferrin receptor antibodies and uses thereof |
| MX2023000984A (es) * | 2020-07-23 | 2023-05-03 | Dyne Therapeutics Inc | Complejos dirigidos al musculo y usos de los mismos para el tratamiento de distrofinopatias. |
-
2022
- 2022-07-08 JP JP2024500480A patent/JP2024525612A/ja active Pending
- 2022-07-08 CA CA3226300A patent/CA3226300A1/en active Pending
- 2022-07-08 WO PCT/US2022/073534 patent/WO2023283619A2/en not_active Ceased
- 2022-07-08 KR KR1020247004294A patent/KR20240032946A/ko active Pending
- 2022-07-08 EP EP22838590.2A patent/EP4367142A4/en active Pending
- 2022-07-08 CN CN202280060769.5A patent/CN118401553A/zh active Pending
- 2022-07-08 US US18/577,472 patent/US20240382609A1/en active Pending
- 2022-07-08 IL IL309911A patent/IL309911A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024525612A5 (enExample) | ||
| JP2024525611A5 (enExample) | ||
| JP2024525613A5 (enExample) | ||
| JP2024527362A5 (enExample) | ||
| JP2024525610A5 (enExample) | ||
| IL309937A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| IL309911A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| IL309935A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| IL309912A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| IL309909A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| JP2023510350A5 (enExample) | ||
| US11771776B2 (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| JP2023535073A5 (enExample) | ||
| US20230088865A1 (en) | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy | |
| US20240117356A1 (en) | Muscle targeting complexes and uses thereof for treating myotonic dystrophy | |
| US20240216522A1 (en) | Muscle targeting complexes and uses thereof for treating friedreich's ataxia | |
| IL309936A (en) | Muscle targeting complexes and formulations for the treatment of dystrophinopathy | |
| CA3226301A1 (en) | Muscle targeting complexes and uses thereof for treating myotonic dystrophy | |
| JP2024540199A (ja) | ジストロフィノパチーを処置するための筋標的化複合体 | |
| US20240398968A1 (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| JP2026503873A (ja) | Ｄｍｄ遺伝子のエクソン４５をスキップするための筋肉標的化複合体およびその使用 | |
| JP2024524222A5 (enExample) | ||
| JP2024540199A5 (enExample) | ||
| IL316206A (en) | Dosage of muscle targeting complexes for the treatment of myotonic dystrophy | |
| IL322946A (en) | Methods and compositions for inhibiting the progression of intramuscular fibrosis |